These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
411 related articles for article (PubMed ID: 26976794)
1. Suppression of Spry1 inhibits triple-negative breast cancer malignancy by decreasing EGF/EGFR mediated mesenchymal phenotype. He Q; Jing H; Liaw L; Gower L; Vary C; Hua S; Yang X Sci Rep; 2016 Mar; 6():23216. PubMed ID: 26976794 [TBL] [Abstract][Full Text] [Related]
2. Isochlorogenic Acid C Reverses Epithelial-Mesenchymal Transition Yu JK; Yue CH; Pan YR; Chiu YW; Liu JY; Lin KI; Lee CJ Anticancer Res; 2018 Apr; 38(4):2127-2135. PubMed ID: 29599331 [TBL] [Abstract][Full Text] [Related]
3. Taiwan cobra cardiotoxin III suppresses EGF/EGFR-mediated epithelial-to-mesenchymal transition and invasion of human breast cancer MDA-MB-231 cells. Tsai PC; Fu YS; Chang LS; Lin SR Toxicon; 2016 Mar; 111():108-20. PubMed ID: 26774845 [TBL] [Abstract][Full Text] [Related]
4. Inhibiting epidermal growth factor receptor signalling potentiates mesenchymal-epithelial transition of breast cancer stem cells and their responsiveness to anticancer drugs. Manupati K; Dhoke NR; Debnath T; Yeeravalli R; Guguloth K; Saeidpour S; De UC; Debnath S; Das A FEBS J; 2017 Jun; 284(12):1830-1854. PubMed ID: 28398698 [TBL] [Abstract][Full Text] [Related]
5. Fangjihuangqi Decoction inhibits MDA-MB-231 cell invasion in vitro and decreases tumor growth and metastasis in triple-negative breast cancer xenografts tumor zebrafish model. Guo Y; Fan Y; Pei X Cancer Med; 2020 Apr; 9(7):2564-2578. PubMed ID: 32037729 [TBL] [Abstract][Full Text] [Related]
6. Suppression of invasion and metastasis of triple-negative breast cancer lines by pharmacological or genetic inhibition of slug activity. Ferrari-Amorotti G; Chiodoni C; Shen F; Cattelani S; Soliera AR; Manzotti G; Grisendi G; Dominici M; Rivasi F; Colombo MP; Fatatis A; Calabretta B Neoplasia; 2014 Dec; 16(12):1047-58. PubMed ID: 25499218 [TBL] [Abstract][Full Text] [Related]
7. SARNP, a participant in mRNA splicing and export, negatively regulates E-cadherin expression via interaction with pinin. Kang GJ; Park MK; Byun HJ; Kim HJ; Kim EJ; Yu L; Kim B; Shim JG; Lee H; Lee CH J Cell Physiol; 2020 Feb; 235(2):1543-1555. PubMed ID: 31313837 [TBL] [Abstract][Full Text] [Related]
8. Growth hormone-releasing hormone induced transactivation of epidermal growth factor receptor in human triple-negative breast cancer cells. Vacas E; Muñoz-Moreno L; Valenzuela PL; Prieto JC; Schally AV; Carmena MJ; Bajo AM Peptides; 2016 Dec; 86():153-161. PubMed ID: 27816751 [TBL] [Abstract][Full Text] [Related]
9. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells. Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795 [TBL] [Abstract][Full Text] [Related]
10. FGF13 promotes metastasis of triple-negative breast cancer. Johnstone CN; Pattison AD; Harrison PF; Powell DR; Lock P; Ernst M; Anderson RL; Beilharz TH Int J Cancer; 2020 Jul; 147(1):230-243. PubMed ID: 31957002 [TBL] [Abstract][Full Text] [Related]
11. Tryptophan hydroxylase 1 and 5-HT Gautam J; Banskota S; Regmi SC; Ahn S; Jeon YH; Jeong H; Kim SJ; Nam TG; Jeong BS; Kim JA Mol Cancer; 2016 Nov; 15(1):75. PubMed ID: 27871326 [TBL] [Abstract][Full Text] [Related]
12. Profilin 2 (PFN2) promotes the proliferation, migration, invasion and epithelial-to-mesenchymal transition of triple negative breast cancer cells. Ling Y; Cao Q; Liu Y; Zhao J; Zhao Y; Li K; Chen Z; Du X; Huo X; Kang H; Chen Z Breast Cancer; 2021 Mar; 28(2):368-378. PubMed ID: 33047272 [TBL] [Abstract][Full Text] [Related]
13. Knockdown of endothelin receptor B inhibits the progression of triple-negative breast cancer. Gu X; Han S; Cui M; Xue J; Ai L; Sun L; Zhu X; Wang Y; Liu C Ann N Y Acad Sci; 2019 Jul; 1448(1):5-18. PubMed ID: 30900271 [TBL] [Abstract][Full Text] [Related]
14. Up-modulation of PLC-β2 reduces the number and malignancy of triple-negative breast tumor cells with a CD133 Brugnoli F; Grassilli S; Lanuti P; Marchisio M; Al-Qassab Y; Vezzali F; Capitani S; Bertagnolo V BMC Cancer; 2017 Sep; 17(1):617. PubMed ID: 28870198 [TBL] [Abstract][Full Text] [Related]
15. AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer. Chen B; Wang J; Dai D; Zhou Q; Guo X; Tian Z; Huang X; Yang L; Tang H; Xie X J Exp Clin Cancer Res; 2017 May; 36(1):65. PubMed ID: 28494797 [TBL] [Abstract][Full Text] [Related]
16. ΔNp63 activates EGFR signaling to induce loss of adhesion in triple-negative basal-like breast cancer cells. Holcakova J; Nekulova M; Orzol P; Nenutil R; Podhorec J; Svoboda M; Dvorakova P; Pjechova M; Hernychova L; Vojtesek B; Coates PJ Breast Cancer Res Treat; 2017 Jun; 163(3):475-484. PubMed ID: 28349272 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of SK4 Potassium Channels Suppresses Cell Proliferation, Migration and the Epithelial-Mesenchymal Transition in Triple-Negative Breast Cancer Cells. Zhang P; Yang X; Yin Q; Yi J; Shen W; Zhao L; Zhu Z; Liu J PLoS One; 2016; 11(4):e0154471. PubMed ID: 27124117 [TBL] [Abstract][Full Text] [Related]
19. Schlafen12 Reduces the Aggressiveness of Triple Negative Breast Cancer through Post-Transcriptional Regulation of ZEB1 That Drives Stem Cell Differentiation. Al-Marsoummi S; Vomhof-DeKrey E; Basson MD Cell Physiol Biochem; 2019; 53(6):999-1014. PubMed ID: 31838790 [TBL] [Abstract][Full Text] [Related]
20. ADAM10: a new player in breast cancer progression? Mullooly M; McGowan PM; Kennedy SA; Madden SF; Crown J; O' Donovan N; Duffy MJ Br J Cancer; 2015 Sep; 113(6):945-51. PubMed ID: 26284334 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]